Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy

Lipids

Volumn 46, Issue 10, 2011, Pages 923-929

  Backes, James M ^a   Gibson, Cheryl A ^a   Ruisinger, Janelle F ^a   Moriarty, Patrick M ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

HMG reductase; Hyperlipidemia; Low density lipoprotein; Plasma lipoproteins; Policosanol

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARCOSANOL; PLACEBO; POLICOSANOL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; AMINO ACIDS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FATTY ALCOHOLS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MIDDLE AGED;

EID: 80054830284     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3591-8     Document Type: Article

References (31)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (see comment). Circulation 106:3143-3421
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart LaBI et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines (erratum appears in Circulation. 2004 Aug 10;110(6):763). Circulation 110:227-239 (Pubitemid 38924592)
3. MH Davidson 2002 Combination therapy for dyslipidemia: safety and regulatory considerations Am J Cardiol 90 20
4. PR Kamstrup A Tybjaerg-Hansen R Steffensen 2009 Nordestgaard BG: Genetically elevated lipoprotein (a) and increased risk of myocardial infarction JAMA 301 2331 2339 19509380 10.1001/jama.2009.801 1:CAS:528: DC%2BD1MXntFCms7w%3D
5. M Janikula 2002 Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 7 203 217 12126462 (Pubitemid 34747609)
6. R Menendez AM Amor RM Gonzalez V Fraga R Mas 1996 Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats Biol Res 29 253 257 9278716 1:STN:280:DyaK2svisVKjsQ%3D%3D (Pubitemid 26176387)
7. R Menendez AM Amor I Rodeiro RM Gonzalez PC Gonzalez JL Alfonso R Mas 2001 Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts Arch Med Res 32 8 12 11282173 10.1016/S0188-4409(00)00265-4 1:CAS:528: DC%2BD3MXivFGmu7k%3D (Pubitemid 32229906)
8. I Gouni-Berthold HK Berthold 2002 Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent Am Heart J 143 356 365 11835043 10.1067/mhj.2002.119997 1:CAS:528:DC%2BD38XitFOmtbw%3D
9. G Castano L Fernandez R Mas J Illnait J Fernandez, et al. 2005 Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia Drugs R D 6 207 219 16050054 10.2165/00126839-200506040-00003 1:CAS:528:DC%2BD2MXos1Cns7g%3D (Pubitemid 40994242)
10. G Castano L Fernandez R Mas J Illnait JC Fernandez, et al. 2003 Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus Clinic Drug Investig 23 639 650 10.2165/00044011-200323100-00003 1:CAS:528:DC%2BD3sXptVCksbs%3D (Pubitemid 37289948)
11. G Castano R Mas JC Fernandez L Fernandez E Alvarez M Lezcay 2000 Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors Curr Ther Res 61 137 146 10.1016/S0011-393X(00)80011-9 1:CAS:528:DC%2BD3cXjtFait7c%3D (Pubitemid 30205447)
12. G Castano R Mas L Fernandez J Illnait S Mendoza R Gamez J Fernandez M Mesa 2005 A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study Drugs Exp Clin Res 31 Suppl 31 44 16444910 1:CAS:528:DC%2BD28XislGgtrc%3D (Pubitemid 43139619)
13. G Castano R Mas L Fernandez J Illnait M Mesa E Alvarez M Lezcay 2003 Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia Drugs Aging 20 153 163 12534315 10.2165/00002512-200320020-00006 1:CAS:528:DC%2BD3sXitVeqs74%3D (Pubitemid 36246297)
14. JT Chen R Wesley RD Shamburek F Pucino G Csako 2005 Meta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol Pharmacotherapy 25 171 183 15767233 10.1592/phco.25.2.171.56942 1:CAS:528:DC%2BD2MXhvFyksrg%3D (Pubitemid 40223479)
15. JC Fernandez R Mas G Castano R Menendez E Alvarez, et al. 2001 Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women Clinic Drug Invest 21 103 113 10.2165/00044011-200121020-00003 1:CAS:528:DC%2BD3MXhvFKns74%3D (Pubitemid 32204821)
16. S Marcello J Gladstein P Tesone R Mas 2000 Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: a pilot study Curr Ther Res 61 346 357 10.1016/S0011-393X(00)80004-1 1:CAS:528: DC%2BD3cXltFKltLY%3D (Pubitemid 30439363)
17. Alcocer LCA, Mas R, Fernandez L (1997) A comparative study of policosanol vs acipimox in patients with type II hypercholesterolemia. Data on File @ http://www.policosanol.com
18. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB (2006) Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 152:982.e1-982.e5
19. HK Berthold S Unverdorben R Degenhardt M Bulitta I Gouni-Berthold 2006 Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial JAMA 295 2262 2269 16705107 10.1001/jama.295.19.2262 1:CAS:528:DC%2BD28Xksl2lsb8%3D (Pubitemid 43736576)
20. Y Lin M Rudrum RP van der Wielen EA Trautwein G McNeill A Sierksma GW Meijer 2004 Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations Metabolism 53 1309 1314 15375787 10.1016/j.metabol.2004.05.006 1:CAS:528:DC%2BD2cXnslehsbw%3D (Pubitemid 39222092)
21. MF Dulin LF Hatcher HC Sasser TA Barringer 2006 Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial Am J Clin Nutr 84 1543 1548 17158441 1:CAS:528:DC%2BD28XhtlGrurbP (Pubitemid 44912842)
22. F Francini-Pesenti D Beltramolli S Dall'acqua F Brocadello 2008 Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia Phytother Res 22 318 322 18167048 10.1002/ptr.2315 1:CAS:528: DC%2BD1cXkslOjtbg%3D (Pubitemid 351397432)
23. F Francini-Pesenti F Brocadello D Beltramolli M Nardi L Caregaro 2008 Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: a double blind, controlled study Complement Ther Med 16 61 65 18514906 10.1016/j.ctim.2007.08.003 1:STN:280:DC%2BD1czltFSnsg%3D%3D
24. A Greyling C De Witt W Oosthuizen JC Jerling 2006 Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects Br J Nutr 95 968 975 16611388 10.1079/BJN20061715 1:CAS:528:DC%2BD28XkvFOlt7c%3D (Pubitemid 43805385)
25. AN Kassis PJ Jones 2006 Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons Am J Clin Nutr 84 1003 1008 17093150 1:CAS:528:DC%2BD28Xht1ahsbjI (Pubitemid 44730368)
26. AN Kassis PJ Jones 2008 Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial Lipids Health Dis 7 17 18447941 10.1186/1476-511X-7-17 (Pubitemid 351713360)
27. Z Reiner E Tedeschi-Reiner Z Romic 2005 Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients Clinic Drug Invest 25 701 707 10.2165/00044011-200525110-00003 (Pubitemid 41577410)
28. CP Marinangeli AN Kassis D Jain N Ebine SC Cunnane PJ Jones 2007 Comparison of composition and absorption of sugarcane policosanols Br J Nutr 97 381 388 17298709 10.1017/S0007114507336763 1:CAS:528:DC%2BD2sXhtFSjsr7O (Pubitemid 46671813)
29. JL Hargrove P Greenspan DK Hartle 2004 Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes Exp Biol Med (Maywood) 229 215 226 1:CAS:528:DC%2BD2cXktlOrur8%3D (Pubitemid 38292099)
30. CJ Porter CW Pouton JF Cuine WN Charman 2008 Enhancing intestinal drug solubilisation using lipid-based delivery systems Adv Drug Deliv Rev 60 673 691 18155801 10.1016/j.addr.2007.10.014 1:CAS:528:DC%2BD1cXitVOmsr4%3D
31. KR Kulkarni 2006 Cholesterol profile measurement by vertical auto profile method Clin Lab Med 26 787 802 17110240 10.1016/j.cll.2006.07.004 (Pubitemid 44724932)